NCT03369327View on ClinicalTrials.gov

Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

PHASE3CompletedINTERVENTIONAL

Enrollment

232

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

December 1, 2018

Conditions

Hepatitis C Virus Infection, Response to Therapy ofHuman Immunodeficiency Virus

Interventions

DRUG

sofosbuvir and daclatasvir

"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg"

Trial Locations (2)

14117

Shariati Hospital, Tehran

Unknown

Emam Hospital, Tehran

All Listed Sponsors

collaborator

RojanPharma Pharmaceutical Company

UNKNOWN

lead

Tehran University of Medical Sciences

OTHER

NCT03369327 - Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter